SC3613 / Korea Kolmar, Dong-A - LARVOL DELTA

SC3613, a Mutant-Selective EGFR Degrader, Demonstrates Improved Safety and Durable Antitumor Activity in Combination with Amivantamab in TKI-Resistant NSCLC (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Clinical • Combination therapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

SC3613 (IN-207387), a mutant-selective EGFR degrader, exhibits potent anti-tumor activity and improved safety profile in EGFR TKI-resistant NSCLC (AACR 2026) - "However, patients with L858R-driven tumors exhibit a poorer prognosis and shorter progression-free survival even with third-generation EGFR TKIs, such as osimertinib, compared with those harboring exon 19 deletions, underscoring a substantial unmet clinical need in this molecular subgroup. Collectively, these findings identify SC3613 as a potent, highly mutant-selective, and orally active EGFR degrader with robust anti-tumor efficacy and improved safety. SC3613 represents a promising next-generation therapeutic candidate for NSCLC patients harboring activating and resistance mutations such as L858R, T790M, and C797S."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Dong-A ST is set to strengthen its presence in global oncology research alongside its subsidiary Aptis by presenting new findings at the American Association for Cancer Research (AACR) 2026. [Google translation] (Korea IT Times) - "In the PARP7 inhibitor category, Dong-A ST will introduce novel candidates designed to simultaneously activate immune responses and suppress tumor growth. Preclinical results showed that some candidates demonstrated significant efficacy as monotherapy and achieved complete remission when combined with anti-PD-1 antibodies or conventional chemotherapy, highlighting strong synergistic potential....SC3613 selectively degrades mutant EGFR, inducing both tumor suppression and immune activation, while showing reduced skin toxicity and improved tolerability compared to existing therapies. Another candidate, SC3499, maintained activity against mutations resistant to osimertinib and demonstrated efficacy with once-daily oral dosing."

Preclinical • Non Small Cell Lung Cancer